Objective To achieve consensus on a definition of remission in SLE (DORIS). Background
Remission is the stated goal for both patient and caregiver, but consensus on a definition of …

Background Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have
been validated to protect against organ damage and to improve quality of life. We aimed to …

Background The unmet need in systemic lupus erythematosus (SLE) with the current
standard of care is widely recognised, but few studies have quantified this. The recent …

Background Targets of treatment for systemic lupus erythematosus (SLE) include the Lupus
Low Disease Activity State (LLDAS), remission, and complete remission. Whether treatment …

Background Evaluating the contribution of glucocorticoid use to organ damage in systemic
lupus erythematosus is confounded by glucocorticoid use in active disease. We sought to …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of
manifestations and potential to affect several organ systems. Complications arise from both …

Objective The prevalence and associations of leucopenia in SLE remain incompletely
understood. We evaluated associations of disease activity and medication use with …

Systemic lupus erythematosus (SLE) cohorts across the world have allowed better
understanding of SLE, including its bimodal mortality, and the impact of social factors and …

Objective Disease activity monitoring in SLE includes serial measurement of anti-double
stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive …

Objective To assess whether Lupus Low Disease Activity State (LLDAS) attainment is
associated with favorable outcomes in patients with recent onset systemic lupus …